BridgeBio Pharma ( (BBIO) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BridgeBio Pharma shares are climbing as analysts highlight strong momentum for its newly launched Attruby treatment and promising trial results for infigratinib in achondroplasia, along with a planned regulatory filing in the second half of 2026. Reflecting this optimism, William Blair initiated coverage with an Outperform rating and a $93.03 fair value, while JPMorgan raised its price target and added the stock to its focus list.
More about BridgeBio Pharma
YTD Price Performance: -14.18%
Average Trading Volume: 2,840,890
Technical Sentiment Signal: Buy
Current Market Cap: $12.73B
For further insights into BBIO stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.